Cardiac Sarcomeric Proteins: Novel Intracellular Targets of Matrix Metalloproteinase-2 in Heart Disease

Trends in Cardiovascular Medicine

Volumn 21, Issue 4, 2011, Pages 112-118

  Ali, Mohammad A M ^a   Fan, Xiaohu ^a   Schulz, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; ALPHA ACTININ; CONNECTIN; CYTOSKELETON PROTEIN; DOXYCYCLINE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; MYOSIN LIGHT CHAIN; PD 166793; PHENANTHROLINE; UNCLASSIFIED DRUG;

APOPTOSIS; HEART DISEASE; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE FUNCTION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REVIEW; SARCOMERE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ANIMALS; ENZYME INHIBITORS; HEART DISEASES; HUMANS; MATRIX METALLOPROTEINASE 2; OXIDATIVE STRESS;

EID: 84861856192     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.03.008     Document Type: Review

References (55)

1. Ahuja P., Perriard E., Perriard J.C., et al. Sequential myofibrillar breakdown accompanies mitotic division of mammalian cardiomyocytes. J Cell Sci 2004, 117:3295-3306.
2. Alfonso-Jaume M.A., Bergman M.R., Mahimkar R., et al. Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol 2006, 291:H1838-H1846.
3. Ali M.A., Cho W.J., Hudson B., et al. Titin is a target of matrix metalloproteinase-2: Implications in myocardial ischemia/reperfusion injury. Circulation 2010, 122:2039-2047.
4. Ali M.A., Chow A.K., Kandasamy A.D., et al. Mechanisms of cytosolic targeting of matrix metalloproteinase-2. J Cell Physiol 2011, [Epub ahead of print].
5. Ali M.A., Schulz R. Activation of MMP-2 as a key event in oxidative stress injury to the heart. Front Biosci 2009, 14:699-716.
6. Bergman M.R., Teerlink J.R., Mahimkar R., et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007, 292:H1847-H1860.
7. Cauwe B., Opdenakker G. Intracellular substrate cleavage: A novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 2010, 45:351-423.
8. Cheung P.Y., Sawicki G., Wozniak M., et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000, 101:1833-1839.
9. Coker M.L., Doscher M.A., Thomas C.V., et al. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 1999, 277:H777-H787.
10. Dormán G., Cseh S., Hajdú I., et al. Matrix metalloproteinase inhibitors: A critical appraisal of design principles and proposed therapeutic utility. Drugs 2010, 70:949-964.
11. Ducharme A., Frantz S., Aikawa M., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000, 106:55-62.
12. Fan X., Schulz R. Matrix metalloproteinase-2: An emerging biomarker for reperfusion injury following percutaneous coronary intervention. Heart 2012, 98:1-2.
13. Ferdinandy P., Danial H., Ambrus I., et al. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 2000, 87:241-247.
14. Fukuda N., Granzier H.L., Ishiwata S., et al. Physiological functions of the giant elastic protein titin in mammalian striated muscle. J Physiol Sci 2008, 58:151-159.
15. Gao C.Q., Sawicki G., Suarez-Pinzon W.L., et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003, 57:426-433.
16. Golub L.M., Lee H.M., Ryan M.E., et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998, 12:12-26.
17. Granzier H.L., Labeit S. The giant protein titin: A major player in myocardial mechanics, signaling, and disease. Circ Res 2004, 94:284-295.
18. Gross J., Lapiere C.M. Collagenolytic activity in amphibian tissues: A tissue culture assay. Proc Natl Acad Sci U S A 1962, 48:1014-1022.
19. Hein S., Scheffold T., Schaper J. Ischemia induces early changes to cytoskeletal and contractile proteins in diseased human myocardium. J Thorac Cardiovasc Surg 1995, 110:89-98.
20. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001, 93:178-193.
21. Hojo Y., Ikeda U., Ueno S., et al. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001, 65:71-75.
22. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998, 32:368-372.
23. Kandasamy A.D., Chow A.K., Ali M.A., et al. Matrix metalloproteinase-2 and myocardial oxidative stress injury: Beyond the matrix. Cardiovasc Res 2010, 85:413-423.
24. King M.K., Coker M.L., Goldberg A., et al. Selective matrix metalloproteinase inhibition with developing heart failure: Effects on left ventricular function and structure. Circ Res 2003, 92:177-185.
25. Lalu M.M., Gao C.Q., Schulz R. Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: A potential role for MMP-9. Mol Cell Biochem 2003, 251:61-66.
26. Lalu M.M., Pasini E., Schulze C.J., et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 2005, 26:27-35.
27. Linask K.K., Han M., Cai D.H., et al. Cardiac morphogenesis: Matrix metalloproteinase coordination of cellular mechanisms underlying heart tube formation and directionality of looping. Dev Dyn 2005, 233:739-753.
28. Massova I., Kotra L.P., Fridman R., et al. Matrix metalloproteinases: Structures, evolution, and diversification. FASEB J 1998, 12:1075-1095.
29. Matsumura Y., Saeki E., Inoue M., et al. Inhomogeneous disappearance of myofilament-related cytoskeletal proteins in stunned myocardium of guinea pig. Circ Res 1996, 79:447-454.
30. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: They're not just for matrix anymore!. Curr Opin Cell Biol 2001, 13:534-540.
31. Meier C.R., Derby L.E., Jick S.S., et al. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999, 281:427-431.
32. Miller J.P., Holcomb J., Al-Ramahi I., et al. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 2010, 67:199-212.
33. Moshal K.S., Rodriguez W.E., Sen U., et al. Targeted deletion of MMP-9 attenuates myocardial contractile dysfunction in heart failure. Physiol Res 2008, 57:379-384.
34. Mujumdar V.S., Smiley L.M., Tyagi S.C. Activation of matrix metalloproteinase dilates and decreases cardiac tensile strength. Int J Cardiol 2001, 79:277-286.
35. Nilsson L., Hallén J., Atar D., et al. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 2012, 98:31-36.
36. Ovechkin A.V., Tyagi N., Rodriguez W.E., et al. Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. J Appl Physiol 2005, 99:2398-2405.
37. Peterson J.T., Hallak H., Johnson L., et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001, 103:2303-2309.
38. Ratajska A., Cleutjens J.P. Embryogenesis of the rat heart: The expression of collagenases. Basic Res Cardiol 2002, 97:189-197.
39. Sariahmetoglu M., Crawford B.D., Leon H., et al. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J 2007, 21:2486-2495.
40. Sariahmetoglu M., Skrzypiec M., Youssef N., et al. Phosphorylation status of matrix metalloproteinase-2 in myocardial ischemia-reperfusion injury. Heart 2012, 98:656-662.
41. Sawicki G., Leon H., Sawicka J., et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: A new intracellular target for matrix metalloproteinase-2. Circulation 2005, 112:544-552.
42. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: Rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007, 47:211-242.
43. Si-Tayeb K., Monvoisin A., Mazzocco C., et al. Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol 2006, 169:1390-1401.
44. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
45. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
46. Strongin A.Y. Mislocalization and unconventional functions of cellular MMPs in cancer. Cancer Metastasis Rev 2006, 25:87-98.
47. Strongin A.Y., Collier I., Bannikov G., et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995, 270:5331-5338.
48. Sung M.M., Schulz C.G., Wang W., et al. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 2007, 43:429-436.
49. Van Eyk J.E., Powers F., Law W., et al. Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: Identification of degradation products and effects on the pCa-force relation. Circ Res 1998, 82:261-271.
50. Viappiani S., Nicolescu A.C., Holt A., et al. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 2009, 77:826-834.
51. Wang G.Y., Bergman M.R., Nguyen A.P., et al. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 2006, 69:688-696.
52. Wang W., Sawicki G., Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002, 53:165-174.
53. Wang W., Schulze C.J., Suarez-Pinzon W.L., et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002, 106:1543-1549.
54. Yaras N., Sariahmetoglu M., Bilginoglu A., et al. Protective action of doxycycline against diabetic cardiomyopathy in rats. Br J Pharmacol 2008, 155:1174-1184.
55. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135.